AOD-9604, a lab-made fragment of human growth hormone, is promoted for fat loss and joint cartilage repair. Human evidence leans against fat loss: the developer's larger study showed no clear weight loss, and today's daily injection is untested in people. In company studies of the oral form, side effects matched placebo except at the highest dose; the main risks stem less from the molecule than from how it is obtained. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track change from own baseline | Fat loss is the claimed effect |
| Body fat mass (DEXA) | No established target; track change from own baseline | Distinguishes fat loss from lean-mass loss |
| Fasting glucose | 70–99 mg/dL | Safety check; a sustained rise prompts stopping |
| HbA1c | 4.0–5.6% | Safety check; average glucose over about 3 months |
| IGF-1 | Age- and sex-specific laboratory range | Safety check; a rise suggests a contaminant or stacked agent |
Cadence: Baseline before starting; weight and waist every 2 weeks; fasting glucose, glycated hemoglobin and IGF-1 at 8–12 weeks and at the end of each course; body composition at the end of each 12-week course